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Prostasin is expressed at the apical surface of normal epithelial cells and suppresses in vitro invasion of cancer cells. Prostasin re-expression in
the PC-3 prostate carcinoma cells down-regulated the epidermal growth factor receptor (EGFR) protein expression and EGF-induced
phosphorylation of the extracellular signal-regulated kinases (Erk1/2). We report here that prostasin and its activating enzyme matriptase are
capable of inducing proteolytic cleavages in the EGFR extracellular domain (ECD) when co-expressed in the FT-293 cells, generating two amino-
terminally truncated fragments EGFR135 and EGFR110, at 135 and 110 kDa. Prostasin's role in EGFR cleavage is dependent on the serine active-
site but not the GPI-anchor. The modifications of EGFR were confirmed to be on the primary structure by deglycosylation. EGFR135 and
EGFR110 are not responsive to EGF stimulation, indicating loss of the ligand-binding domains. EGFR110 is constitutively phosphorylated and in
its presence Erk1/2 phosphorylation is increased in the absence of EGF. The protease-induced EGFR cleavages are not dependent on EGFR
phosphorylation. The EGFR ECD proteolytic modification by matriptase–prostasin is also observed in the BEAS-2B normal lung epithelial cells,
the BPH-1 benign prostate hyperplasia and the MDA-MB-231 breast cancer cell lines; and represents a novel mechanism for epithelial cells to
modulate EGF-EGFR signaling.
© 2007 Elsevier B.V. All rights reserved.Keywords: ErbB receptor tyrosine kinase; GPI-anchor; Transmembrane glycoprotein; Extracellular signal-regulated kinase; MT-SP1; PRSS81. Introduction
Prostasin (PRSS8), a glycosylphosphatidylinositol (GPI)-
anchored extracellular membrane serine protease [1], is
ubiquitously expressed in epithelial tissues such as the bladder,
colon, kidney, lung, prostate, breast, skin, and placenta [2,3].
Prostasin has been shown to play many functional roles in
epithelial physiology, including activation of the epithelial
sodium channel (ENaC) [4–6], suppression of in vitro invasion
[7,8], maintenance of epidermal integrity [9], and regulation of⁎ Corresponding author. Department of Molecular Biology and Microbiology,
University of Central Florida, Building 20, Room 323, 4000 Central Florida
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doi:10.1016/j.bbamcr.2007.10.019inflammation-induced gene expression [10]. The promoter of
the prostasin gene is positively regulated by sterol regulatory
element binding proteins (SREBP's) and negatively regulated
by SNAI family transcription factors [11,12]. Matriptase, a
type-II transmembrane extracellular serine protease coordi-
nately expressed with prostasin in normal tissues [13], activates
the prostasin zymogen by a site-specific cleavage [14]. The
active prostasin is regulated by serine protease inhibitors such as
the hepatocyte growth factor activator inhibitor-1B (HAI-1B)
[2] and protease nexin-1 (PN-1) [15].
Down-regulation of prostasin expression is associated with
high-grade and hormone refractory prostate cancers [7,16]. In
an androgen-independent human prostate carcinoma cell line
PC-3, prostasin expression is greatly compromised partly due to
promoter DNA hypermethylation, while re-expression of
prostasin reduced cell invasion through the Matrigel without
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shown that the expression of several invasion-promoting
molecules is regulated by prostasin re-expression in the PC-3
cells. The gene expression regulation is potentially mediated by
a protein-level down-regulation of the epidermal growth factor
receptor (EGFR) [17]. As a result, the cellular response to EGF
was reduced as shown by the down-regulation of EGF-
stimulated phosphorylation of the extracellular signal-regulated
kinases (Erk1/2). The expression of SLUG, urokinase-type
plasminogen activator (uPA), uPA receptor (uPAR), inducible
nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and
granulocyte-macrophage colony stimulating factor (GM-CSF)
was also down-regulated by prostasin in the PC-3 cells.
EGFR, a member of the ErbB (erythroblastic leukemia viral
(v-erb-b) oncogene) family of receptor tyrosine kinases (RTK's),
plays pivotal roles in many diverse cellular responses ranging
from proliferation to apoptosis, migration to adhesion, and
differentiation to depolarization [18,19]. Dys-regulation of
EGFR-initiated cell signaling as a result of over-expression or
constitutively activating mutations is causative to at least 10
different types of solid tumor [20–24]. The PC-3 prostate cancer
cells express an abundance of EGFR and its ligands [25,26],
creating an autocrine signaling loop to confer the cells with
highly invasive properties. Inhibition of EGFR signaling could
be the mechanism of reduced invasiveness of PC-3 cells re-
expressing prostasin [17], either through down-regulation of
uPA–uPAR signaling [27,28] or up-regulation of cell adhesion
molecules such as the E-cadherin [29]. The PC-3 cell line is not
dependent on EGFR signaling for proliferation [30], and the
prostasin re-expression had no effect on cell growth [7]. Our
observations in the PC-3 cells re-expressing prostasin were
consistent with a mechanism of proteolytic modification of the
EGFR in its extracellular domain (ECD) because prostasin is an
active extracellular serine protease. We did not observe,
however, a truncated EGFR fragment in the PC-3 cells with
prostasin re-expression, potentially due to rapid internalization
of the cleaved receptor. In this report, we present biochemical
evidence that prostasin induces site-specific cleavages of the
EGFR ECD following activation by matriptase in FT-293 cells.
The amino-terminally truncated EGFR fragments were char-
acterized for their response to EGF, tyrosine phosphorylation,
and impact on cell signaling.
2. Materials and methods
2.1. Materials
A full-length human EGFR cDNA (Clone No. PR1116_D04, corresponding
to GenBank™ sequence NM_005228) was purchased from OriGene Technol-
ogies, Inc. (Rockville, MD). A Flp-In T-REx derivative of the human embryonic
kidney cell line HEK-293, designated FT-293, and a recombinant human EGF
were purchased from Invitrogen Corporation (Carlsbad, CA). Polyclonal
antibodies against human prostasin [1] and mouse PN-1 [15] were described
previously. A polyclonal antibody to EGFR (sc-03), a monoclonal antibody to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (sc-32233), and a
polyclonal antibody to Erk1/2 (sc-94) were purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA). A polyclonal antibody to phospho-EGFR
(Tyr1068, #2234) and a monoclonal antibody to the HA-Tag (6E2, #2367) were
purchased from Cell Signaling Technology, Inc. (Danvers, MA). A monoclonalantibody to phospho-tyrosine (PY-20, #03-7799) was purchased from Zymed
Laboratories, Inc. (South San Francisco, CA). Monoclonal antibodies to
phospho-Akt (#550747) and Akt (#610860) were purchased from BD
Biosciences (Franklin Lakes, NJ). A polyclonal antibody to phospho-Erk1/2
(V803A) was purchased from Promega Corporation (Madison, WI). Tyrphostin
AG1478 (#658548) was purchased from EMD Chemicals, Inc. (San Diego,
CA). The BEAS-2B normal human lung epithelial cells were purchased from the
American Type Culture Collection (Manassas, VA). The BPH-1 human benign
prostate hyperplasia cells were kindly provided by Dr. SimonW. Hayward of the
Vanderbilt University Medical Center (Nashville, TN). The MDA-MB-231
human breast carcinoma cells were kindly provided by Dr. Janet E. Price of the
MD Anderson Cancer Center (Houston, TX).
2.2. Construction of expression plasmids
The full-length human EGFR cDNA clone fromOriGene was subcloned into
the pcDNA3 plasmid (Invitrogen), generating the EGFR expression plasmid
pcDNA3-EGFR. The EGFR ECD deletion mutant plasmid pcDNA3-EGFRΔ2-
7 was generated by polymerase chain reaction (PCR) using the following
primers: 5′-TTT CTT TTC CTC CAG AGC CCG ACT CGC C -3′ and 5-AAT
TAT GTG GTG ACA GAT CAC GGC TCG TGC GTC -3′. The pcDNA3-
EGFRΔ2-7 encodes a mutant EGFR with a deletion of exons 2–7 (amino acid
residues 6–272). The prostasin expression plasmids pcDNA3-Pro and pcDNA3-
ProM have been described previously [10]. The plasmid pcDNA3-ProMG,
coding for a GPI-anchor-free but protease-competent human prostasin, was
generated by PCR, using the following primers: 5′-GCT CGATAC AAT AAA
CGC CA-3′ and 5′-GGA AGC TTC ACC TCA GCA AGC CCT GGG-3′. A
pcDNA3-HA plasmid was generated by inserting into pcDNA3 a double-
stranded oligonucleotide encoding a 9-amino acid residue segment of the
influenza Avirus hemagglutinin (HA) tag (YPYDVPDYA). A full-length human
matriptase cDNA [31]was subcloned into the pcDNA3-HAplasmid to generate a
carboxyl-terminally HA-tagged matriptase expression plasmid pcDNA3-Mat-
HA. A plasmid encoding an active-site mutant matriptase, pcDNA3-MatM-HA
was generated using the QuikChange Site-DirectedMutagenesis Kit (Stratagene,
La Jolla, CA). The serine active-site was changed to an alanine in pcDNA3-
MatM-HA. A plasmid, pcDNA3-EGFR-HA, encoding a carboxyl-terminally
HA-tagged EGFR was also created. All plasmids were verified by DNA
sequencing.
2.3. Cell culture, transfection and western blot
The FT-293 cells were cultured in the D-MEM (High Glucose) medium
supplemented with 10% (v/v) fetal bovine serum (FBS, Atlanta Biologicals,
Inc., Lawrenceville, GA). For transfection experiments cells were plated on
poly-L-lysine (PLL)-coated 12-well plates at a density of 4×105 cells/well. On
the second day, appropriate expression plasmids (0.8 μg of total DNA per
transfection) were transfected into the cells using the Lipofectamine 2000
reagent (Invitrogen, 2 μl/transfection) according to the manufacturer's protocol.
The BEAS-2B cells were cultured in BEBM (Lonza, Walkersville, MD), and set
in 12-well plates at a density of 3×105 cells/well for transfections. The BPH-1
cells were cultured in RPMI-1640 medium supplemented with 5% FBS, and set
in 6-well plates at a density of 5×105 cells/well for transfections. The MDA-
MB-231 cells were cultured in MDA medium (MEM with 5% FBS, 1× sodium
pyruvate, 1× non-essential amino acids, 1× glutamine, and 2× vitamins), and set
in 6-well plates at a density of 1×106 cells/well for transfections. At 24 h after
transfection, the cells were lysed in the RIPA lysis buffer [1] supplemented with
a protease inhibitor cocktail. 20 μg (for FT-293 and BEAS-2B transfectants) or
40 μg (for BPH-1 and MDA-MB-231 transfectants) of total protein per sample
were subjected to western blot analysis with appropriate antibodies. Each
membrane was also blotted with a GAPDH antibody as a control of protein
loading.
2.4. Deglycosylation of EGFR
Deglycosylation of the recombinant EGFR expressed in FT-293 cells and
those cleaved by the proteases was carried out using an Enzymatic Protein
Deglycosylation Kit (E-DEGLY, Sigma-Aldrich, St. Louis, MO), following the
Fig. 1. Prostasin is activated by matriptase in FT-293 cells. FT-293 cells were transfected with cDNA's encoding the wild-type prostasin (Pro, 0.5 μg), a serine active-
site mutant prostasin (ProM, 0.5 μg), an HA-tagged matriptase (Mat-HA, 0.3 μg) or an HA-tagged serine active-site mutant matriptase (MatM-HA, 0.3 μg), or in
combinations as indicated in the figure. Each transfection was carried out with an equal amount of total plasmid DNA (0.8 μg) using the vector plasmid pcDNA3 (Vec)
as a substitute when appropriate. At 24 h post transfection, cells were subjected to PN-1 binding assays with mouse seminal vesicle fluid followed by western blot
analysis for prostasin and PN-1. Gel electrophoresis was performed with SDS under boiling and reducing conditions. The positions of the covalent prostasin-PN-1
complex (82 kDa), prostasin zymogen (40 kDa), and prostasin (38 kDa) are indicated by arrows. The specific prostasin-PN-1 complex band is indicated by the asterisk.
The results shown are representative of three independent experiments. WB: western blot.
Fig. 2. Prostasin and matriptase induce EGFR ECD cleavages in FT-293 cells. (A and B) FT-293 cells were transfected with cDNA's encoding EGFR, wild-type
prostasin (Pro, 0.2 μg), serine active-site mutant prostasin (ProM, 0.2 μg), anchor-free mutant prostasin (ProMG, 0.2 μg), HA-tagged matriptase (Mat-HA, 0.1 μg) or
HA-tagged serine active-site mutant matriptase (MatM-HA, 0.1 μg), or in combinations as indicated in the figure. Each sample was transfected with an equal amount
of the EGFR plasmid (0.5 μg) and an equal amount of total plasmid DNA (0.8 μg) using the vector plasmid pcDNA3 (Vec) as a substitute when appropriate. At 24 h
post transfection, cells were assayed for EGFR protein expression by SDS-PAGE and western blot analysis with an anti-EGFR antibody that recognizes a carboxyl-
terminal intracellular epitope of EGFR. The membrane was re-blotted with a GAPDH antibody as a sample loading control. The results shown are representative of
three independent experiments. (C) Deglycosylation (DeGly) of EGFR and protease-cleaved EGFR was performed before western blot analysis with an EGFR
antibody to show primary structure modifications of EGFR.
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PAGE (7.5% gel) and western blot analysis with 30 μg of total protein per
sample.
2.5. PN-1 cell binding assay
FT-293 cells transfected with matriptase and prostasin expression plasmids
were washed with 1× PBS once, scraped off in 1× PBS and collected by
centrifugation. The cell pellet was then re-suspended in 100 μl of 25 mM Tris–
HCl, pH 7.6, and incubated with 5 μl of mouse seminal vesicle fluid at 37 °C for
2 h as described previously [1]. Following the incubation, the cells were pelleted
and lysed with 1% SDS in 25 mM Tris–HCl, pH 7.6 for western blot analysis
with a prostasin antibody [1] and a PN-1 antibody [15].
2.6. EGF treatment of cells and analysis of EGF-EGFR signaling
pathway activation
FT-293 cells transfected with EGFR, matriptase, and prostasin expression
plasmids were serum-starved for 24 h, treated with 10 ng/ml of EGF for 10 min,
or left untreated, before western blot analysis for phospho-EGFR and total
EGFR, phospho-Erk1/2 and total Erk1/2, or phospho-Akt and total Akt. Each
membrane was also blotted with a GAPDH antibody as a control of protein
loading. For EGFR phosphorylation inhibition assays, FT-293 cells were treated
with AG1478 (2 μM), or DMSO (solvent control) during transfection, serum-
starvation, and EGF stimulation.Fig. 3. EGFR110 is constitutively active and activates Erk1/2. (A) FT-293 cells were
lanes 2 and 4), wild-type prostasin (P, 0.2 μg), or HA-tagged matriptase (M, 0.1 μg)
with an equal amount of total plasmid DNA (0.8 μg) using the vector plasmid pcDNA
under serum-free medium for overnight and treated with 10 ng/ml EGF for 10 min (la
EGFR protein expression and EGFR tyrosine phosphorylation (pTyr and pEGFR/pY1
control. The results shown are representative of three independent experiments. (B
(0.3 μg), with or without wild-type prostasin (P, 0.2 μg) and HA-tagged matriptase (
equal amount of total plasmid DNA (0.8 μg) using the vector plasmid pcDNA3 as a
serum-free medium for 24 h before western blot analysis for phosphorylated Erk
representative of three independent experiments.3. Results
3.1. Prostasin activated by matriptase induces cleavages of
EGFR in FT-293 cells
In the previous study [17], a proteolytic mechanism of EGFR
regulation by prostasin was suggested from the observation that
re-expression of prostasin down-regulated EGFR protein expres-
sion in the PC-3 cells. To determinewhether EGFR is a biological
substrate of prostasin, we co-expressed EGFR, prostasin and an
HA-tagged matriptase in the FT-293 cells. The FT-293 cells were
derived from the human embryonic kidney cell line HEK-293
which does not express significant levels of EGFR [32,33],
prostasin [1] or matriptase (data not shown). First, we evaluated
activation of prostasin co-expressed with matriptase (Mat-HA,
HA-tagged, same hereon) by performing a binding assay with
PN-1. The PN-1 binding assay is a reliable method for evaluating
prostasin's serine protease activation state in vitro and in vivo
[1,14,15]. When expressed without matriptase, prostasin
remained in the zymogen form and no prostasin-PN-1 complex
was detected in the binding assay, indicating a lack of serine
protease activity (Fig. 1, lane 2). When co-expressed withtransfected with cDNA's encoding EGFR (0.05 μg for lanes 1 and 3; 0.2 μg for
, or in combinations as indicated in the figure. Each transfection was carried out
3 as a substitute when appropriate. At 24 h after transfection, cells were placed
nes 3 and 4) or left untreated (lanes 1 and 2) before western blot analysis for total
068). The membrane was re-blotted with a GAPDH antibody as a sample loading
) FT-293 cells were transfected with cDNA's encoding EGFRΔ2-7 or EGFR
M, 0.1 μg) as indicated in the figure. Each transfection was carried out with an
substitute when appropriate. At 24 h after transfection, cells were placed under
1/2 (pErk) and Akt (pAkt), Total Erk, and Total Akt. The results shown are
Fig. 4. Protease-induced EGFR cleavages are independent of EGFR
phosphorylation. FT-293 cells were treated with AG1478 (2 μM, lanes 5–8),
or with DMSO (solvent control of AG1478, lanes 1–4) during transfection,
serum-starvation, and EGF stimulation. Cells were transfected with cDNA's
encoding EGFR, wild-type prostasin (P, 0.2 μg), or HA-tagged matriptase
(M, 0.1 μg), or in combinations as indicated in the figure. Each sample was
transfected with an equal amount of the EGFR plasmid (0.3 μg) and an equal
amount of total plasmid DNA (0.8 μg) using the vector plasmid pcDNA3 (Vec)
as a substitute when appropriate. At 24 h after transfection, cells were placed
under serum-free medium for overnight and treated with 10 ng/ml of EGF for
10 min (lanes 3, 4, 7 and 8) or left untreated (lanes 1, 2, 5 and 6) before western
blot analysis for EGFR and phosphorylated EGFR (EGFRpY1068). The results
shown are representative of three independent experiments.
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matriptase, to produce a lower molecular weight prostasin, and at
the same time a prostasin-PN-1 complex (Fig. 1, lane 5). The
cleaved prostasin is active as shown by its ability to form the
covalent complex with its cognate serpin PN-1. In the prostasin
and the PN-1 western blots, the upper band indicated by an
asterisk is the prostasin-PN-1 complex; other high-molecular
weight bands are unidentified. The serine active-site mutant
prostasin was also cleaved by matriptase but no prostasin-PN-1
complex was observed (Fig. 1, lane 6). The serine active-site
mutant matriptase, expectedly, was unable to cleave and activate
the prostasin zymogen (Fig. 1, lanes 8–9). We also performed
western blots to evaluate the expression of Mat-HA and MatM-
HA. An active form and the zymogen form were observed for
Mat-HA but only the zymogen form was seen for MatM-HA
(data not shown), as expected from previous results [31].
Next we examined the EGFR protein co-expressed with
matriptase and prostasin by western blot analysis using a
polyclonal antibody that specifically recognizes a carboxyl-
terminal intracellular epitope of the human EGFR. Because
matriptase and prostasin are both extracellular proteases, any
proteolytic action on the EGFR protein would result in amino-
terminal ECD truncation on the outside of the cell. The truncated
fragments would be detectable by an antibody against the
carboxyl-terminal region of the receptor. Two modified EGFR
fragments were produced when matriptase was co-expressed
(Fig. 2A, middle panel, long exposure, lane 4), detected at
approximately 135 kDa and 110 kDa (named EGFR135 and
EGFR110). Quantities of these truncated EGFR, EGFR135 and
EGFR110, were greatly increased when the wild-type prostasin
was co-expressed with EGFR and matriptase (Fig. 2A, lane 5).
There was no increase in quantities of EGFR135 and EGFR110
when the serine active-site mutant prostasin was co-expressed
with EGFR and matriptase (Fig. 2A, lane 6). The amount of
uncut full-length EGFR at 170 kDa was reduced with matriptase
co-expression, and to a much greater extent with the addition of
the wild-type prostasin (Fig. 2A, upper panel, short exposure,
lanes 4 and 5). The serine active-site mutant matriptase (MatM-
HA) was unable to induce any cleavage of EGFR, with or
without prostasin (Fig. 2A, lanes 7–9).
To determine whether the membrane anchorage of prostasin
is required for inducing EGFR cleavage, we generated a GPI-
anchor-free but protease-competent prostasin for co-expression
with EGFR and matriptase. The GPI-anchor-free prostasin was
secreted into the culture medium and undetectable in the cell
lysate (data not shown), confirming previous findings on this
type of prostasin mutant [34]. The GPI-anchor-free prostasin
produced a similar pattern of EGFR cleavage as that seen with
the wild-type prostasin when co-expressed with matriptase
(Fig. 2B, lane 6), suggesting that the GPI membrane anchorage
is not required for the active prostasin-induced EGFR cleavage.
To determine if the EGFR135 and EGFR110 fragments were
the products of primary structure modification, or other potential
processes, such as differential glycosylation, we performed an
enzymatic deglycosylation experiment for EGFR co-expressed
with matriptase–prostasin. As shown in Fig. 2C, the deglyco-
sylation step resulted in expected shifts of the apparentmolecular mass for the full-length EGFR (from 170 kDa to
140 kDa), EGFR135 (to 100 kDa), and EGFR110 (to 80 kDa).
Three distinct EGFR protein molecules or fragments can still be
detected in the western blot after deglycosylation, ruling out
differential glycosylation as a mechanism for producing
EGFR135 and EGFR110 and supporting an amino-terminal
ECD truncation mechanism.
3.2. EGFR110 is constitutively active
To evaluate the impact of the protease-induced EGFR ECD
cleavages on cell signaling, FT-293 cells presenting uncleaved
or cleaved EGFR were assayed for changes in phosphorylation
states of EGFR and downstream signaling molecules Erk1/2
and Akt. The full-length EGFR (170 kDa) remained in the
unphosphorylated state under the serum-free culture condition
and became highly tyrosine-phosphorylated once stimulated
with EGF (Fig. 3A). The EGFR110 fragment was shown to be
tyrosine-phosphorylated under the serum-free culture condition,
i.e., in the absence of EGF (Fig. 3A, lane 2), but was not
responsive to EGF stimulation (Fig. 3A, lane 4). There was an
apparent reduction of tyrosine-phosphorylated EGFR110 in the
EGF-treated sample. The EGFR135 fragment did not present
detectable tyrosine phosphorylation under either the serum-free
or the EGF-stimulated condition. Expression of EGFRΔ2-7,
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[35], led to increased Erk1/2 phosphorylation under the serum-
free culture condition when compared with the cells expressing
the wild-type EGFR (Fig. 3B, upper panels, lanes 1 and 2). In
cells where EGFR was co-transfected with prostasin and
matriptase (i.e., presenting the tyrosine-phosphorylated
EGFR110), Erk1/2 phosphorylation was increased to a similar
extent as the cells expressing EGFRΔ2-7 (Fig. 3B, upper panels,
lane 3). On the other hand, Akt phosphorylation was not affected
in these cells (Fig. 3B, lower panels).
3.3. Protease-induced EGFR cleavages are not dependent on
tyrosine phosphorylation
When EGFR was over-expressed in the FT-293 cells, a small
portion of the receptor appeared tyrosine-phosphorylated
(Fig. 4, lane 1). To determine whether this auto-phosphorylation
of EGFR is required for the protease-induced cleavage, we
performed co-transfection experiments in the presence of
AG1478, a potent inhibitor of EGFR kinase activity and auto-
phosphorylation. Incubation with AG1478 completely abol-
ished not only the auto-phosphorylation and EGF-stimulated
phosphorylation of the wild-type EGFR, but also the cleavage-
induced phosphorylation of EGFR110 (Fig. 4, middle panel,
lanes 5–8). On the other hand, the proteases induced the specific
EGFR cleavages in the presence of AG1478 (Fig. 4, upper
panel, lane 5–8), suggesting that the protease-induced EGFR
cleavages are independent of receptor tyrosine phosphorylation.
3.4. Matriptase and prostasin induce EGFR ECD cleavages in
BEAS-2B, BPH-1, and MDA-MB-231 cells
To determine if the protease-induced EGFR cleavages occur
in other cell lines, we performed EGFR/protease co-transfectionFig. 5. Matriptase and prostasin induce EGFR ECD cleavages in BEAS-2B,
BPH-1, and MDA-MB-231 cells. BEAS-2B, BPH-1, and MDA-MB-231 cells
were transfected with cDNA's encoding EGFR-HA (0.6 μg), wild-type
prostasin (Pro, 0.4 μg), and wild-type matriptase (Mat, 0.2 μg) in combinations
as indicated in the figure. Each sample was transfected with an equal amount of
total plasmid DNA (1.2 μg) using the vector plasmid pcDNA3 (Vec) as a
substitute when appropriate. At 24 h post transfection, cells were assayed for
EGFR-HA protein expression by SDS-PAGE and western blot analysis with an
anti-HA antibody (upper panels). The membrane was re-blotted with a GAPDH
antibody as a sample loading control (lower panels). The results shown are
representative of three independent experiments.experiments in normal human lung epithelial cells BEAS-2B,
the human benign prostate hyperplasia cell line BPH-1, and the
human breast carcinoma cell line MDA-MB-231. As shown in
Fig. 5, the actions of the matriptase and prostasin serine protease
cascade produced the same EGFR ECD cleavages observed in
the FT-293 cell line, generating the EGFR135 and EGFR110
fragments in BPH-1 and MDA-MB-231. The EGFR135
fragment was not detected in the BEAS-2B cells under the
experiment conditions but the EGFR110 fragment was clearly
present in these cells.
4. Discussion
Prostasin as a GPI-anchored protein is routed to the apical
membrane of the normally polarized epithelial cells [1]. EGFR
and matriptase are normally routed to the basolateral sides of the
cells [13,36]. Topologically distinct but coordinate expression
of matriptase and prostasin is observed in many terminally
differentiated epithelial tissues, suggesting coordinate roles for
these two serine proteases in normal epithelial physiology [13].
But during epithelial carcinogenesis expression of matriptase
and prostasin begins to show divergent patterns of change,
suggesting diverging and independent roles for the two serine
proteases in cancer. In the prostate and the breast, prostasin is
abundantly expressed in the normal tissue, but down-regulated
in cancers [7,8]. An exception may be the ovarian cancer, which
is marked by an up-regulation of prostasin [37]. For matriptase,
its expression is up-regulated in prostate and breast cancers
[38,39], and its mechanistic role in cancer is believed to be
activating the ligands of the Ron signaling pathway [40]. In
terminally differentiated epithelial tissues, EGFR is not ex-
pressed in abundance, but over-expression of EGFR is com-
monly associated with cancer [41–43]. In the normal tissue,
prostasin and matriptase are controlled by topological separa-
tion on the plasma membrane, if not also by differential expres-
sion, i.e., a high abundance of prostasin and a low abundance of
matriptase. We may view prostasin as a sensor or surveillance
agent for epithelial polarity and integrity. Once an insult, e.g.,
inflammation, results in injury of the normal epithelium,
depolarization ensues and injury repair programs are mobilized.
EGFR is a key player in epithelial injury repair [44] but at some
point the cells need to initiate a “stop program” of EGFR
signaling to allow epithelial differentiation and re-polarization.
The executor of the “stop program” appears to be prostasin or
related proteases, activated or re-expressed to initiate terminal
differentiation. Prostasin's role in this regard is in complete
agreement with the observation that in prostasin-knocked-out
mouse skin, terminal differentiation of the skin epithelium is
defective, marked by lack of tight junction formation and
absence of occludin expression [9]. Also in agreement with this
model is the observation that prostasin expression is down-
regulated during inflammation while forced prostasin expres-
sion attenuates inflammation-induced gene expression [10].
Silencing of prostasin by epigenetic events or growth factors
and cytokines [8,10,11,15], would be a prerequisite for tu-
morigenesis and gain of aggressive properties such as invasion
and metastasis.
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EGF-EGFR signaling and suppress invasion in some cells, but
produce an autoactivated EGFR110 in others with up-regulation
of downstream signals.We reason that the overall cellular impact
of the protease-induced EGFR cleavage is dependent on the rate
of internalization for the cleaved receptor. In cells with normal or
even accelerated turnover rate, such as the PC-3 [45], the net
effect is inhibition of EGF-EGFR signaling due to reduced cell
surface receptor presentation. We predict for cancer cells that are
EGFR-dependent this will be the predominant phenotype as in
these cells the EGF-EGFR signaling is tightly coupled with
receptor internalization [46]. In these cells, the rapid receptor
internalization could also have prevented our detection of the
cleaved forms of EGFR in our previous study [17]. In cells with
impeded receptor internalization, such as the HEK-293 and its
derivatives (the FT-293) [47], the net effect is a constitutively
activated truncated EGFR remaining on the membrane, activat-
ing the downstream signals. Cells that are EGFR-over-expres-
sing but are not EGFR-dependent would present this phenotype.
The HA-tagged matriptase was confirmed for its ability to
activate prostasin in the FT-293 cells when the two proteases
were co-expressed from their full-length cDNA's (Fig. 1).
Matriptase is also capable of cleaving the EGFR at apparently
the same sites cleaved by prostasin, but appeared to be a less
effective enzyme in this role (Fig. 2A, compare lanes 4 and 5).
Matriptase action on EGFR could be amplified, however, if an
abundance of matriptase is expressed, as was seen in PC-3 cells
transfected with the serine active-site mutant prostasin [17]. In
these cells, we now know that the mutant prostasin is incapable
of cleaving EGFR, but the robustly induced matriptase certainly
could. We attribute the EGFR ECD cleavages to matriptase and
prostasin but we do not have evidence for a direct interaction
between matriptase and EGFR, or between prostasin and EGFR.
The molecular landscape of the membrane-anchored or
membrane-associated serine proteases is still expanding. We
are limited by our knowledge of this new family of proteases to
determine whether the EGFR ECD is potentially cleaved by a
downstream protease activated by prostasin. We did not observe
a significant induction of matriptase expression in the FT-293
cells expressing prostasin (data not shown), ruling out a solo
matriptase action on EGFRwhen active prostasin is also present.
The EGFR ECD contains the ligand-binding domains that
form the target of the monoclonal antibody (Mab) drug ImClone
C225/cetuximab/Erbitux [48], approved for advanced head-and-
neck and colorectal cancers as a third-line treatment option
[49,50]. The matriptase→prostasin→EGFR cascade can play a
critical role in anti-EGFR therapies for cancer using Mab
drugs targeting the ECD. The cleaved EGFR, EGFR135 and
EGFR110, are no longer responsive to EGF stimulation
(Fig. 3A), presumably due to the loss of the ligand-binding
domains, all or partial. By this reasoning, Erbitux or similar Mab
drugs targeting the ligand-binding domains of EGFR would no
longer be effective. If the cleaved EGFR is retained on the
membrane and activates downstream signaling, it will likely
result in lower cell sensitivity to the Mab drugs, i.e., requiring
higher doses for growth inhibition. In this scenario, protease
inhibitors specific for the matriptase–prostasin cascade may beconsidered as an appropriate adjuvant. If the proteolytic
cleavage of EGFR results in its rapid internalization and
turnover [17], drug sensitivity to the Mab's should increase,
i.e., showing growth inhibition at a lower dose. In this scenario,
prostasin, pre-activated or activated upon reaching the cancer
cells by their endogenously over-expressed matriptase or related
proteases, may be used as an adjuvant. We have shown that the
role of prostasin in EGFR ECD cleavage is not dependent on its
membrane anchorage via the GPI (Fig. 2B), making it a suitable
candidate for development of a systemically deliverable agent to
treat certain cancers that are dependent on over-expressed EGFR
for growth and survival signals.
5. Conclusions
We have identified EGFR as a biological substrate for the
epithelial extracellular serine protease activation cascade invol-
ving matriptase and prostasin. The protease-induced EGFR
ECD cleavage activates the receptor tyrosine kinase but the
impact on cell signaling varies between different cell types,
probably due to differences in receptor internalization rate. The
novel protease-activated EGFR signal modulation mechanism
may have clinical implications in therapies for treating cancers
by targeting the EGFR ECD.
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